<DOC>
	<DOCNO>NCT00000694</DOCNO>
	<brief_summary>To define best dos sargramostim ( granulocyte-macrophage colony-stimulating factor ; GM-CSF ) , interferon alfa-2b ( IFN-A2b ) , zidovudine ( AZT ) give together patient AIDS-associated Kaposi 's sarcoma ( KS ) , learn side effect drug give together 8 week , find whether combination GM-CSF , IFN-A2b , AZT effect KS , HIV , immune system . Studies show IFN-A2b cause KS tumor shrink disappear 30 percent patient . IFN-A2b greatly reduce growth HIV virus test tube experiment perhaps patient . AZT also show reduce growth HIV show improvement immune system few infection . Test tube experiment show IFN-A2b AZT use together , reduce growth HIV virus much effectively either drug use alone . In recent study combination interferon alpha AZT patient KS , 40 percent patient show shrinkage tumor , show evidence suppression HIV growth body . However , combination IFN-A2b AZT often cause marked lowering white blood cell ( WBC ) count , especially type WBC call granulocyte ( neutrophil ) important body 's defense infection . Recombinant human GM-CSF human protein produce bacteria . It show cause increase WBC count .</brief_summary>
	<brief_title>A Phase I Trial Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor ( rHuGM-CSF ) , Recombinant Alpha Interferon Azidothymidine ( AZT ) AIDS-Associated Kaposi 's Sarcoma</brief_title>
	<detailed_description>Studies show IFN-A2b cause KS tumor shrink disappear 30 percent patient . IFN-A2b greatly reduce growth HIV virus test tube experiment perhaps patient . AZT also show reduce growth HIV show improvement immune system few infection . Test tube experiment show IFN-A2b AZT use together , reduce growth HIV virus much effectively either drug use alone . In recent study combination interferon alpha AZT patient KS , 40 percent patient show shrinkage tumor , show evidence suppression HIV growth body . However , combination IFN-A2b AZT often cause marked lowering white blood cell ( WBC ) count , especially type WBC call granulocyte ( neutrophil ) important body 's defense infection . Recombinant human GM-CSF human protein produce bacteria . It show cause increase WBC count . AMENDED : 900910 allow one patient treat beyond one year . Original design : GM-CSF , IFN-A2b , AZT give every day 8 week . There 6 patient per dose level . IFN-A2b GM-CSF give two separate injection skin ( subcutaneous injection ) day . AZT give orally every 4 hour ( 6 times/day ) . The first patient give dos drug quite well tolerated give alone . If dosage tolerate without serious side effect , dosage IFN-A2b increase subsequent group patient . Maintenance treatment consist dose receive conclusion initial 8 week course treatment resume eligible patient 1 year .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>AIDS-Related Opportunistic Infections</mesh_term>
	<mesh_term>Molgramostim</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Prophylaxis Pneumocystis carinii pneumonia ( PCP ) aerosolize pentamidine . Ibuprofen , exceed 1600 mg/day , fever analgesia . Biopsyproven Kaposi 's sarcoma confine skin , lymph node , nonnodular lesion hard palate . Positive antibody HIV confirm federally license ELISA test kit . Patients must able give informed consent . Allowed : Basal cell carcinoma . Exclusion Criteria Coexisting Condition : Patients follow exclude : Prior concurrent opportunistic infection B symptom ( unexplained fever , night sweat , &gt; 10 percent involuntary weight loss diarrhea persist &gt; 2 week ) . Visceral ( nonnodal ) Kaposi 's sarcoma include extensive oral lesion . Severe ( &gt; 2+ ) tumorassociated edema . Concurrent neoplasia ( exclude basal cell carcinoma ) . Significant cardiac disease ( New York Heart Association class III IV ) history myocardial infarction significant cardiac arrhythmia . Dementia ( = &gt; stage 2 ) . Concurrent Medication : Excluded : Any systemic chemoprophylaxis specifically allow . Aspirin acetaminophen . Nonsteroidal antiinflammatory agent specifically allow . Corticosteroids . Barbiturates . Other antiviral agent , immunotherapy , hormonal therapy , chemotherapy direct treatment viral infection malignancy . Other investigational agent . Concurrent Treatment : Excluded : Radiation therapy direct treatment viral infection malignancy . Patients follow exclude : Prior concurrent opportunistic infection B symptom ( unexplained fever , night sweat , &gt; 10 percent involuntary weight loss diarrhea persist &gt; 2 week ) . Visceral ( nonnodal ) Kaposi 's sarcoma include extensive oral lesion . Severe ( &gt; 2+ ) tumorassociated edema . Concurrent neoplasia ( exclude basal cell carcinoma ) . Significant cardiac disease ( New York Heart Association class III IV ) history myocardial infarction significant cardiac arrhythmia . Dementia ( = &gt; stage 2 ) . Prior Medication : Excluded : Interferon alpha2b . Granulocytemacrophage colonystimulating factor ( GMCSF ) . Prior grade 3 grade 4 toxicity AZT therapy . Excluded within 30 day study entry : Zidovudine ( AZT ) . Corticosteroids . Biologic response modifier . Cytotoxic chemotherapy . Antiretroviral agent . Toxicity grade accord NIAID Recommendations Grading Acute Subacute Toxic Effects ( Adults ) . Prior Treatment : Excluded within 30 day study entry : Requirement red blood cell transfusion within 30 day study entry . Radiation therapy . Active drug alcohol abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Immune System</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>